Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNAseq of Huh7 and Huh7.5 cells treated with interferon alpha, beta or lambda.

ABSTRACT: RNAseq of Huh7 and Huh7.5 cells treated with interferon alpha, beta or lambda.

PROVIDER: PRJEB44928 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR5919430_1.fastq.gz	Fastqsanger.gz
	ERR5919430_2.fastq.gz	Fastqsanger.gz
	ERR5919440_1.fastq.gz	Fastqsanger.gz
	ERR5919440_2.fastq.gz	Fastqsanger.gz
	ERR5919450_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 86

Similar Datasets

RNAseq of Huh7 and Huh7.5 cells treated with interferon alpha, beta or lambda.

Project description:The transcriptome of Huh7 and Huh7.5 was sequenced from cells treated with interferon alpha (IFNα), beta (IFNβ) or lambda (IFNλ) for 8 hours. Each treatment was compared to respective mock-treated cells in 6 pairwise comparisons, for a total of 43 samples classified in 12 experimental conditions. Cells were treated for 8h with 10ng/ml of Interferon-α2A, 5000 U/ml of Interferon-β1A or 100ng/ml of interferon-λ3 prior RNA extraction and library preparation. Mock-treated cells were used as control for each treatment. 3 to 4 biological replicates were analysed for each biological condition. Libraries for Illumina sequencing were constructed by polyA selection with the Illumina Kit. A paired end (2x100) run was performed.

2021-08-17 | E-MTAB-10469 | biostudies-arrayexpress

Pharmacological inhibition of tyrosine kinase 2 preserves interferon-λ-mediated protection (neutrophils)

Project description:Treating inflammatory diseases with Janus kinase 1/2 (JAK1/2) inhibitors bears the risk that patients acquire viral infections due to unwanted immune suppression. Tyrosine kinase 2 (TYK2), a JAK family member, is required for type I interferon (IFN-α/β) signaling, but its role in type III IFN (IFN-λ) signaling is still under debate. We found that the selective TYK2 inhibitor BMS-986165 blocked potentially noxious type I IFN signaling without altering IFN-λ-mediated gene expression. We show that epithelial cells do not require TYK2 for IFN-λ-mediated signaling or antiviral protection. Lack of TYK2 diminished IFN-α-induced protection against lethal influenza virus infection of mice, but did not impair IFN-λ-mediated antiviral protection. Our findings suggest that selective TYK2 inhibitors likely represent a superior treatment option for type I interferonopathies than broadly acting JAK1/2 inhibitors, as selective TYK2 inhibitors may counteract inflammatory responses without abolishing the beneficial antiviral effects of IFN-λ.

2021-04-09 | GSE146103 | GEO

Interferon response in Huh7 cells

Project description:Interferon response in Huh7 cells

| PRJNA649769 | ENA

Pharmacological inhibition of tyrosine kinase 2 preserves interferon-λ-mediated protection (airway epithelial cells)

2021-04-09 | GSE146102 | GEO

CRISPR screen for interferon-alpha inducible inhibitors of yellow fever virus replication

Project description:Host cells produce interferon (IFN) in response to viral infections. Secreted interferon results in the transcription and production of hundreds of interferon-stimulated genes (ISGs). A genome-wide CRISPR screen using IFN alpha-treated Huh7.5 cells was performed to determine which ISGs were required in order for host cells to suppress yellow fever virus (YFV) infection.

2018-10-25 | GSE121710 | GEO

Interferon lambda promotes immune dysregulation and tissue inflammation in TLR7-induced lupus [scRNA-seq]

Project description:Interferon lambdas share important functional similarities with type I interferons, but their role in inflammation and autoimmune disease remains controversial and is not well studied. Here, we present the first evidence that interferon lambda is pathogenic and has nonredundant functions in TLR7-associated lupus inflammation. Most notably, we found that interferon lambda promotes systemic immune dysregulation through localized effects in the skin and kidneys. These data identify a novel role for interferon lambda in lupus immunobiology and tissue-specific pathology.

2020-05-15 | GSE142637 | GEO

Type-I interferon signatures in SARS-CoV-2 infected Huh7 cells

Project description:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes Coronavirus disease 2019 (COVID-19) has caused a global health emergency. A key feature of COVID-19 is dysregulated Interferon-response. Type-I interferon (IFN-I) is one of the earliest antiviral innate immune responses following viral infection and plays a significant role in pathogenesis of SARS-CoV-2. In this study, using a proteomics-based approach, we identified that SARS-CoV-2 infection induces delayed and dysregulated IFN-I signaling in Huh7 cells. We demonstrate that SARS-CoV-2 is able to inhibit RIG-I mediated IFN- production. Our results also confirm the recent findings that IFN-I pretreatment is able to reduce susceptibility of Huh7 cells to SARS-CoV-2, but not post-treatment. Senescent Huh7 cells in spite of showing accentuated IFN-I response were more susceptible to SARS-CoV-2 infection and SARS-CoV-2 effectively inhibited IFIT1 in these cells. Proteomic comparison between SARS-CoV-2, SARS-CoV and MERS-CoV revealed a distinct differential regulatory signature of interferon-related proteins emphasizing that therapeutic strategies based on observations in SARS-CoV and MERS-CoV should be used with caution. Our findings provide a better understanding of SARS-CoV-2 regulation of cellular interferon response and a perspective on its use as a treatment. Characterization of the role of different interferon stimulated genes on the inhibition of SARS-CoV-2 pathogenesis may direct novel antiviral strategies.

2021-05-18 | PXD023450 | Pride

mRNA microarray analysis of gene changes in Huh7 cells treated with IFN-λ4, IFN-λ1 and IFN-α

Project description:The change of gene expression in Huh7 cells treated with IFN-λ4, IFN-λ1 and IFN-α was analyzed at 0h, 6h and 16h after different interferon treatments.

2016-08-08 | GSE83085 | GEO

Interferon-stimulated gene expression in STAT1 knockout cells

Project description:STAT1 plays a cental role in the induction of interferon-stimulated genes, but interferon alpha can activate a STAT1-independent pathway that leads to gene expression. We performed microarray analysis to examine whether like interferon alpha, interferon lambda, a newly discovered interferon, can induce the expression of interferon-stimulated genes in the absence of STAT1. Control and STAT1 knockout Huh-7.5 hepatoma cells were left untreated or treated with 1000 U/ml of human interferon alpha 2a or interferon lambda 1 (PBL) for 24 h, and total RNA was extracted. Sense-strand DNA was generated from 200 ng of total RNA, fragmented, and labeled using a GeneChip WT Plus Reagent Kit (Affymetrix). Six samples were obtained and each sample was anlyzed using one GeneChip.

2016-07-22 | E-GEOD-84693 | biostudies-arrayexpress

Induced Hepatocyte-Like Cells with Interferon timecourse

Project description:This experiment investigates the transcriptional effect of Interferon Alpha or Interferon Lambda upon Induced Hepatocyte-Like Cells (iHLCs). Peginterferon lambda-1a (Lambda) is a type III interferon that acts through a unique receptor complex expressed primarily on hepatocytes. In Phase 2b clinical studies, a combined regimen of Lambda with ribavirin (RBV) was associated with more rapid declines in viral load compared to a peginterferon alfa (PEGASYS; alfa) plus RBV regimen. This correlated with improved virologic response rates at Weeks 4 and 12 of treatment. To gain insight into the potential molecular mechanisms of these early robust responses with Lambda, we investigated the effects of alfa and Lambda on transcription in iHLCs obtained from Cellular Dynamics.. These samples are a subset of a larger experiment to be published at a later date.

2015-01-31 | E-MTAB-2477 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data